ClinicalTrials.gg
CompletedNCT04178577Updated Nov 27, 2020

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

A Phase 1 interventional study of Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in Renal Impairment, sponsored by Spero Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2020, 6 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
185th of 468
39 · median 32
Started
2019
with 24 others
Phase 1
232 of 553
14 open now
Registered
410th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 185th largest by enrollment of the 468 interventional ones that give a count, is one of 25 that started in 2019, is one of 232 in phase 1, and was the 410th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.

03

Conditions studied

  • Renal Impairment

Keywords

  • End State Renal Disease (ESRD)
  • Renal Insufficiency
  • Renal Impairment
  • Renal Disease
  • Hemodialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Adult males or females, 18 years of age or older.
  • ≥ 18.5 and ≤ 39.9 (kg/m2) and weight between 50.0 and 130.0 kg
  • Medically healthy without abnormalities (Healthy Volunteers) or medically stable without clinically significant acute or chronic illness (Subjects with Renal Disease).
  • Non-smoker for at least 1 month prior to screening for the study.
  • Ability and willingness to abstain from alcohol, caffeine, xanthinecontaining beverages or food.

Key Exclusion Criteria:

  • Any clinically significant medical history or abnormal findings upon physical examination, or clinical laboratory tests, not specifically excluded in other criteria below that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • (ECG) with interval duration equal or greater than 500 msec
  • (HB), hematocrit (HCT), white blood cell count (WBC), or count less than the lower limit of normal range of the reference laboratory (Cohort 1). HB \< 8.5 gm/dL, WBC ≤ 3,000 cells/μL or platelet count ≤ 100,000 cells/μL (Cohorts 2-5).
  • Results of biochemistry tests for (ALT), aspartate aminotransferase (AST) and greater than 1.5 X the (ULN) for the reference laboratory.
  • Recent history of known or suspected Clostridium difficile infection.
  • History of known genetic metabolism anomaly associated with carnitine deficiency (e.g., carnitine transporter defect, methylmalonic aciduria, propionic academia).
  • History of chronic liver disease, cirrhosis, or biliary disease.
  • History of seizure disorder except childhood history of febrile seizures.
  • Positive urine drug/alcohol testing.
  • Positive testing for (HIV), surface antigen (HBsAg) or (HCV) antibodies.
  • History of substance abuse or alcohol abuse.
  • Use of antacids within 24 hours prior to study drug administration.
  • Known history of clinically significant reaction or anaphylaxis to any medication.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

    Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

Interventions

06

What researchers measure

Primary outcomes

  1. Apparent total body clearance (CL/F).

    Time frame: 72 hours post dose

  2. Area under the curve from time zero to the last quantifiable sample (AUC0-last).

    Time frame: 72 hours post dose

  3. Area under the curve extrapolated to infinity (AUC0-∞).

    Time frame: 72 hours post dose

  4. Apparent steadystate volume of distribution (Vss/F).

    Time frame: 72 hours post dose

  5. Maximum plasma concentration (Cmax).

    Time frame: 72 hours post dose

  6. Time to the maximum plasma concentration (Tmax).

    Time frame: 72 hours post dose

  7. Terminal elimination half-life (t1/2).

    Time frame: 72 hours post dose

Secondary outcomes

  1. Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.

    AEs will be categorized by system organ class (SOC) and AE preferred term (PT).

    Time frame: 14 days post last dose

  2. Significant changes from baseline in clinical laboratory values.

    All laboratory data will be summarized by cohort, and at each scheduled time-point using descriptive statistics (n, mean, SD, median, minimum, and maximum). E.g. of laboratory values: hematology, biochemistry, coagulation and urinalysis

    Time frame: 14 days post last dose

  3. Significant changes from baseline in physical examination.

    Changes in baseline in physical examination findings (Normal, Abnormal NCS, Abnormal CS) will be summarized using counts and percentages by cohort, and will also be listed individually for each scheduled time-point. Physical examination will include: HEENT; cardiovascular, respiratory, gastrointestinal, dermatological, musculoskeletal, nervous systems, lymph nodes and general appearance. Additional body systems may be evaluated at the Investigator's discretion.

    Time frame: 14 days post last dose

  4. Significant changes from baseline in vitals signs.

    Vital sign values and changes from baseline at each scheduled time-point will be summarized by cohort for the Safety Analysis Population using descriptive statistics (n, mean, SD, median, minimum, and maximum). Vitals signs will include: systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature.

    Time frame: 14 days post last dose

  5. Significant changes from baseline in ECG

    Overall evaluation of safety ECGs will be summarized by cohort, using frequency counts and percentage of subjects as normal or abnormal, and the relevance of the abnormality will be summarized by CS or NCS. ECG parameters will include: heart rate, RR interval, PR interval, QRS, QT and QTcF

    Time frame: 14 days post last dose

  6. Renal clearance (CLR)

    Time frame: 72 hours post dose

  7. Fraction of drug excreted in the urine expressed as a percentage of the TBPM-PI-HBr dose administered (Ae%).

    Time frame: 72 hours post dose

  8. Amount of drug excreted in the urine through 24 hours (Ae0-24), through 48 hours (Ae0-48) and through 72 hours (Ae0-72) for Cohorts 1-4.

    Time frame: 72 hours post dose

  9. For subjects on dialysis, estimated hemodialysis clearance (CLHD) will be assessed.

    Time frame: Up to 1 day post dose - between start and end of hemodialysis.

  10. For subjects on dialysis, the extraction ratio (ER) will be assessed.

    Time frame: Up to 1 day post dose - between start and end of hemodialysis.

  11. For subjects on dialysis, the amount of the dose removed by hemodialysis (XHD) will be assessed.

    Time frame: Up to 1 day post dose - between start and end of hemodialysis.

Other outcomes

  1. For subject in Cohort 1, cumulative amount of TBPM metabolite excreted in urine.

    Time frame: 72 hours post dose

  2. For subjects in Cohort 1, cumulative urinary excretion of TBPM and TBPM metabolite as a % of dose administered.

    Time frame: 72 hours post dose

07

Study locations

2 sites
  • Medical Facility
    Miami, Florida 33136, United States
  • Medical Facility
    Orlando, Florida 32809, United States
08

References and documents

Publications

  • Patel G, Rodvold KA, Gupta VK, Bruss J, Gasink L, Bajraktari F, Lei Y, Jain A, Srivastava P, Talley AK. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. Antimicrob Agents Chemother. 2022 May 17;66(5):e0240721. doi: 10.1128/aac.02407-21. Epub 2022 Apr 14. PubMed 35420493 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Sep 2020, 9 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 26, 2019
StartActual
Dec 6, 2019
Primary completionActual
Sep 6, 2020
CompletionActual
Sep 11, 2020
Last update
Nov 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04178577
Lead sponsor
Spero Therapeutics
Responsible party
Sponsor
First posted
Nov 26, 2019
Start date
Dec 6, 2019
Primary completion
Sep 6, 2020
Completion
Sep 11, 2020
Last update
Nov 27, 2020

Study contacts

David Melnick, M.D.
study director · Spero Therapeutics Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion